Holen Sie sich die Stockscreener-App
93.09
1.05%
0.97
Schlusskurs vom Vortag:
$92.12
Offen:
$91.73
24-Stunden-Volumen:
649.61K
Relative Volume:
0.69
Marktkapitalisierung:
$23.38B
Einnahmen:
$3.26B
Nettoeinkommen (Verlust:
$-1.45B
KGV:
-15.86
EPS:
-5.871
Netto-Cashflow:
$1.18B
1W Leistung:
-0.62%
1M Leistung:
+2.98%
6M Leistung:
-12.07%
1J Leistung:
-17.40%
1-Tages-Spanne:
$90.52
$93.24
1-Wochen-Bereich:
$90.52
$94.25
52-Wochen-Spanne:
$79.52
$124.00
Biontech Se Adr Stock (BNTX) Company Profile
Compare BNTX vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
93.09 | 23.30B | 3.26B | -1.45B | 1.18B | -5.871 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-02 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2026-01-16 | Hochstufung | Goldman | Neutral → Buy |
| 2025-06-05 | Bestätigt | H.C. Wainwright | Buy |
| 2025-05-29 | Eingeleitet | Goldman | Neutral |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2025-01-10 | Eingeleitet | Truist | Buy |
| 2024-12-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2024-11-19 | Eingeleitet | Berenberg | Buy |
| 2024-11-19 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-11-08 | Hochstufung | Goldman | Neutral → Buy |
| 2024-09-24 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-17 | Hochstufung | Jefferies | Hold → Buy |
| 2024-09-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-08-07 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-08-02 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-14 | Eingeleitet | Evercore ISI | In-line |
| 2024-02-23 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-01-05 | Eingeleitet | Oppenheimer | Perform |
| 2023-12-01 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-10-16 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-17 | Hochstufung | Redburn | Neutral → Buy |
| 2022-12-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-08-17 | Eingeleitet | Cowen | Market Perform |
| 2022-07-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2021-12-16 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-11-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Hold |
| 2021-10-07 | Eingeleitet | Jefferies | Hold |
| 2021-08-11 | Hochstufung | Bryan Garnier | Neutral → Buy |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-06-16 | Herabstufung | Redburn | Neutral → Sell |
| 2021-05-18 | Eingeleitet | Goldman | Neutral |
| 2021-05-11 | Herabstufung | Bryan Garnier | Buy → Neutral |
| 2020-12-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-08-03 | Fortgesetzt | Berenberg | Buy |
| 2020-07-21 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-30 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-19 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-04-28 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-03-18 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-03-09 | Eingeleitet | H.C. Wainwright | Neutral |
| 2020-01-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-01-22 | Herabstufung | UBS | Buy → Neutral |
| 2019-11-05 | Eingeleitet | Wolfe Research | Outperform |
| 2019-11-04 | Eingeleitet | Berenberg | Buy |
| 2019-11-04 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-04 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-11-04 | Eingeleitet | JP Morgan | Overweight |
| 2019-11-04 | Eingeleitet | SVB Leerink | Outperform |
| 2019-11-04 | Eingeleitet | UBS | Buy |
Alle ansehen
Biontech Se Adr Aktie (BNTX) Neueste Nachrichten
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
BIONTECH SE BIONTECH SE ADR (0A3M.L) Q1 FY2026 earnings call transcript - Yahoo Finance
BioNTech Just Named a New CEO. Here's What Guido Oelkers' Appointment Means for the Stock. - The Motley Fool
BioNTech SE (BNTX) stock price, news, quote and history - Yahoo Finance Australia
BioNTech (BNTX) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Pfizer Rises Almost 7% Post Q2 Results: How to Play the Stock - TradingView
Bank of America Corp DE Raises Stake in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech (BNTX) Institutional Ownership 2026 - MarketBeat
BioNTech's Double Whammy: A CEO Transition Lands in the Middle of a Guidance Cut () - aktiencheck.de
Assenagon Asset Management S.A. Makes New $39.38 Million Investment in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech's Second Quarter Puts a Founder's Exit and a Shrinking COVID Franchise in Sharp Relief - aktiencheck.de
Bank of New York Mellon Corp Trims Stock Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Pfizer and BioNTech Advance Next‑Season Pediatric COVID‑19 Booster Strategy With New Phase 3 Update - TipRanks
Pfizer and BioNTech Advance Variant-Adapted COVID-19 Booster in New Phase 4 Study - TipRanks
BioNTech SE Sponsored ADR Revenue Breakdown – BSESOF:22UA - TradingView
Caution with BioNTech! Novo Nordisk Accelerates! Buying Opportunity in Vidac Pharma Stock? - news.financial
Pfizer and BioNTech Lock In Next-Gen Pediatric COVID Booster Edge - TipRanks
BioNTech Earnings Call: COVID Slide, Oncology Push - TipRanks
BioNTech SE Sponsored ADR $BNTX Shares Purchased by Amundi - MarketBeat
BioNTech SE (BNTX) Stock Forecasts - Yahoo Finance
BioNTech's Promising Oncology Pipeline Is Now in Late-Stage Development - morningstar.com
Earnings call transcript: BioNTech Q2 2026 revenue falls, shares slip premarket - Investing.com
BioNTech Q2 Earnings Call Highlights - Yahoo Finance
Weekly Recap: BioNTech CEO succession and Q2 2026 loss forecast - TradingView
BioNTech earnings on deck as losses widen amid COVID decline - Investing.com
Biontech Se Sponsored Adr (BNTXN) Q4 2022 Earnings ReportResults, Call & Slides - TipRanks
Enterprise value to revenue forward of BioNTech SE Sponsored ADR – BX:22UA - TradingView
Spontaneous reporting of adverse reactions... : Porto Biomedical Journal - Ovid
Hsbc Holdings PLC Sells 31,445 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
First Trust Advisors LP Acquires 451,124 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
Aristides Capital LLC Decreases Holdings in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Biontech Se Sponsored Adr (BNTXN) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Biontech Se Sponsored Adr (BNTXN) Q1 2026 Earnings ReportResults, Call & Slides - TipRanks
Biontech Se Sponsored Adr (BNTXN) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Biontech Se Sponsored Adr (BNTXN) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Biontech Se Sponsored Adr (BNTXN) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Biontech Se Sponsored Adr (BNTXN) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
Biontech Se Sponsored Adr (BNTXN) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Biontech Se Sponsored Adr (0A3M) Q4 2022 Earnings ReportResults, Call & Slides - TipRanks
Biontech Se Sponsored Adr (BNTXN) Earnings Dates, Call Summary & Reports - TipRanks
BioNTech’s $1 Billion Buyback Can’t Drown Out the Noise From Patent Battles () - aktiencheck.de
Biontech Se Sponsored Adr (0A3M) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Biontech Se Sponsored Adr (0A3M) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
BioNTech Faces Fresh Patent Offensive as Buyback Signals Confidence, Pipeline Data Loom - aktiencheck.de
What to Watch in Pfizer's Non-Oncology Portfolio This Earnings Season - TradingView
BioNTech SE (0A3M) to Announce Q2 2026 Financial Results and Host Investor Call on August 4 - Kalkine Media
Amova Asset Management Americas Inc. Invests $6.91 Million in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Biontech Se Sponsored Adr (BNTX) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Biontech Se Sponsored Adr (BNTX) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Biontech Se Sponsored Adr (BNTX) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
Finanzdaten der Biontech Se Adr-Aktie (BNTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):